Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 125-131 , Summer 2009

Mesothelioma: Path to Multimodality Treatment

  • Stacey Su, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Stacey Su, MD, Department of Surgery, University of Pennsylvania School of Medicine, University of Pennsylvania Health System, 3400 Spruce Street, 6 Silverstein Pavillion, Philadelphia, PA 19104

References 

  1. Lieutaud J: Historia anatomic—Medica, etc. Paris, 1767, p 86
  2. Smith D. The history of mesothelioma. In:  Pass H,  Vogelzang N,  Carbone M editor. Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. New York, NY: Springer Verlag; 2005;p. 1–20
  3. Du Bray E, Rosson F. Primary mesothelioma of the pleura: A clinical and pathologic contribution to pleural malignancy, with a report of a case. Arch Intern Med. 1920;26:715–737
  4. Stout A, Murray MR. Localized pleural mesothelioma. Arch Pathol. 1942;34:951–964
  5. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–271
  6. Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and mesothelioma. N Engl J Med. 1965;272:560–565
  7. Selikoff IJ. Lung cancer and mesothelioma during prospective surveillance of 1249 asbestos insulation workers, 1963-74. Ann NY Acad Sci. 1976;271:448–456
  8. OSHA: Work-Related Lung Disease Surveillance Report 2007: US Department of Health and Human Services, National Institute for Occupational Safety and Health, ed. Cincinnati, OH, 2008
  9. Environmental Protection Agency. EPA asbestos materials bans: Clarification. 1999;Washington, DC
  10. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol. 2002;29:2–17
  11. Lopez-Rios F, Illei P, Rusch V, et al. Absence of SV40 DNA and RNA in human pleural mesotheliomas: High risk of false positive DNA results with use of primers prone to amplify SV40 sequences present in common laboratory plasmids. Mod Pathol. 2004;17(suppl 1):340A
  12. Pancaldi C, Balatti V, Guaschino R, et al. Simian virus 40 sequences in blood specimens from healthy individuals of Casale Monferrato, an industrial town with a history of asbestos pollution. J Infect. 2009;58:53–60
  13. Renshaw AA, Dean BR, Antman KH, et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111:106–109
  14. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients (Part 2: Prognosis and staging). Cancer. 1993;72:394–404
  15. Boutin C, Loddenkemper R, Astoul P. Diagnostic and therapeutic thoracoscopy: Techniques and indications in pulmonary medicine. Tuber Lung Dis. 1993;74:225–239
  16. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura (Experience with 29 patients). Thorax. 1976;31:15–24
  17. Jaklitsch M, Wiener D, Bueno R, et al. The development of the Brigham and Women's multimodality treatment plan for malignant pleural mesothelioma: A model for improving the treatment of rare diseases. In:  Pass H,  Vogelzang N,  Carbone M editor. Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. New York, NY: Springer; 2005;p. 696–722
  18. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma (From the International Mesothelioma Interest Group). Chest. 1995;108:1122–1128
  19. Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111:815-825, discussion, 825-826
  20. Sugarbaker DJ, Mentzer SJ, DeCamp M, et al. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest. 1993;103:377S–381S
  21. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993;11:1172–1178
  22. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63discussion, 63-65
  23. Tsao AS, Wistuba I, Roth JA, et al. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081–2090
  24. Kindler HL, Belani CP, Herndon JE, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC # 626715) with or without leucovorin rescue for malignant mesothelioma (Sequential Phase I trials by the Cancer and Leukemia Group B). Cancer. 1999;86:1985–1991
  25. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura (A Phase I study). Br J Cancer. 1992;65:956–960
  26. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  27. Zidar BL, Green S, Pierce HI, et al. A Phase I evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group study. Invest New Drugs. 1988;6:223–226
  28. Pennucci MC, Ardizzoni A, Pronzato P, et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: A Phase I FONICAP trial (Italian Lung Cancer Task Force). Cancer. 1997;79:1897–1902
  29. Samson MK, Wasser LP, Borden EC, et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and Adriamycin versus cyclophosphamide and Adriamycin in patients with advanced stage malignant mesothelioma: A Sarcoma InterGroup study. J Clin Oncol. 1987;5:86–91
  30. Samuels BL, Herndon JE, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A Phase I study by the Cancer and Leukemia Group B. Cancer. 1998;82:1578–1584
  31. Dirix LY, van Meerbeeck J, Schrijvers D, et al. A Phase I trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol. 1994;5:653–655
  32. Carmichael J, Cantwell BM, Harris AL. A Phase I trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol. 1989;25:911–912
  33. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: A disease unaffected by current therapeutic maneuvers. J Clin Oncol. 1988;6:527–535
  34. Law MR, Gregor A, Hodson ME, et al. Malignant mesothelioma of the pleura: A study of 52 treated and 64 untreated patients. Thorax. 1984;39:255–259
  35. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol. 1989;7:1157–1168
  36. Rusch VW. Trials in malignant mesothelioma (LCSG 851 and 882). Chest. 1994;106:359S–362S
  37. Rusch VW, Figlin R, Godwin D, et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: A Lung Cancer Study Group Trial. J Clin Oncol. 1991;9:313–319
  38. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg. 1999;68:1799–1804
  39. Pass HI, Kranda K, Temeck BK, et al. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann Surg Oncol. 1997;4:215–222
  40. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–626
  41. Rice TW, Adelstein DJ, Kirby TJ, et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1994;58:24–29
  42. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:367–372
  43. Shiraishi Y, Nakajima Y, Koyama A, et al. Morbidity and mortality after 94 extrapleural pneumonectomies for empyema. Ann Thorac Surg. 2000;70:1202–1206discussion, 1206-1207
  44. Worn H. (Chances and results of surgery of malignant mesothelioma of the pleura (author's transl)). Thoraxchir Vask Chir. 1974;22:391–393
  45. Rusch VW, Rosenzweig K, Venkatraman E, et al. A Phase I trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795
  46. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63:334–338
  47. Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183–1189
  48. Flores RM, Routledge T, Seshan VE, et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2008;136:605–610
  49. Sugarbaker DJ, Grondin SC. Techniques of pneumonectomy (Pleural pneumonectomy). Chest Surg Clin North Am. 1999;9:379–392xi
  50. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1991;102:10–14discussion, 14-15
  51. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma (Results in 120 consecutive patients). Ann Surg. 1996;224:288–294discussion, 294-296
  52. Antman KH, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980;68:356–362
  53. Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: The role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol. 1987;18:67–74
  54. Montag AG, Pinkus GS, Corson JM. Keratin protein immunoreactivity of sarcomatoid and mixed types of diffuse malignant mesothelioma: An immunoperoxidase study of 30 cases. Hum Pathol. 1988;19:336–342
  55. O'Hara CJ, Corson JM, Pinkus GS, et al. ME1 (A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies). Am J Pathol. 1990;136:421–428
  56. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–146
  57. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–11
  58. Markman M, Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol. 1992;118:547–550
  59. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  60. Rusch VW, Niedzwiecki D, Tao Y, et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: Pharmacokinetic studies. J Clin Oncol. 1992;10:1001–1006
  61. Carroll N, Mohamed F, Sugarbaker P. Hyperthermic chemoperfusion, and postoperative chemotherapy: The National Cancer Institute and Washington Hospital Center experience. In:  Pass H,  Vogelzang N,  Carbone M editor. Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis and Translational Therapies. New York, NY: Springer; 2005;p. 732–754
  62. Wagmiller J, Koehan M, Chabot J, et al. Peritoneal mesothelioma: The Columbia experience. In:  Pass H,  Vogelzang N,  Carbone M editor. New York, NY: Springer; 2005;p. 723–731
  63. Sauter ER, Langer C, Coia LR, et al. Optimal management of malignant mesothelioma after subtotal pleurectomy: Revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol. 1995;60:100–105
  64. Colleoni M, Sartori F, Calabro F, et al. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori. 1996;82:53–56
  65. Chang MY, Sugarbaker DJ. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: Techniques and complications. Thorac Surg Clin. 2004;14:523–530
  66. Chang MY, Sugarbaker DJ. Innovative therapies: Intraoperative intracavitary chemotherapy. Thorac Surg Clin. 2004;14:549–556
  67. Janne PA, Baldini EH. Patterns of failure following surgical resection for malignant pleural mesothelioma. Thorac Surg Clin. 2004;14:567–573
  68. Mujoomdar AA, Sugarbaker DJ. Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2008;20:298–304
  69. Zellos L, Richards WG, Capalbo L, et al. A Phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2009;137:453–458
  70. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451–3457
  71. Krug LM, Pass HI, Rusch VW, et al. Multicenter Phase I trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27:3007–3013
  72. Albelda SM. Gene therapy for lung cancer and mesothelioma. Chest. 1997;111:144S–149S
  73. Pass HI, Temeck BK, Kranda K, et al. Phase II randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1997;4:628–633
  74. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a Phase I clinical trial in malignant mesothelioma. Hum Gene Ther. 1998;9:1083–1092
  75. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol. 2002;29:41–50
  76. Pass HI, DeLaney TF, Tochner Z, et al. Intrapleural photodynamic therapy: Results of a Phase I trial. Ann Surg Oncol. 1994;1:28–37
  77. Castagneto B, Zai S, Mutti L, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a Phase I study on 31 consecutive patients. Lung Cancer. 2001;31:303–310
  78. Schouwink H, Rutgers ET, van der Sijp J, et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: Dose finding and toxicity results. Chest. 2001;120:1167–1174
  79. Friedberg JS, Mick R, Stevenson JP, et al. Phase I trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol. 2004;22:2192–2201
  80. Gordon GJ, Rockwell GN, Godfrey PA, et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res. 2005;11:4406–4414

PII: S1043-0679(09)00082-3

doi: 10.1053/j.semtcvs.2009.07.006

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 125-131 , Summer 2009

Article Tools